熊去氧胆酸联合多潘立酮或莫沙必利治疗原发性胆汁反流性胃炎的疗效分析
|
摘要
目的比较熊去氧胆酸联合多潘立酮或联合莫沙必利治疗原发性胆汁反流性胃炎(PBRG)的疗效。方法选取2017年5月—2018年8月收治的PBRG患者86例,随机分为A组与B组各43例。A组采用熊去氧胆酸联合多潘立酮治疗,B组采用采用熊去氧胆酸联合莫沙必利治疗。治疗1个月后,比较2组临床疗效、临床症状评分以及不良反应发生情况。结果 A组总有效率为83. 72%,高于B组的76. 74%,差异无统计学意义(P> 0. 05)。治疗1个月后,2组腹痛、饱胀、恶心、呕吐等临床症状评分较治疗前明显下降,且A组上述症状评分均低于B组,但差异无统计学意义(P> 0. 05)。A组不良反应发生率为9. 30%,低于B组的13. 95%,差异无统计学意义(P> 0. 05)。结论熊去氧胆酸联合多潘立酮或莫沙必利治疗PBRG患者安全有效,能明显改善患者胃部不适症状,且不良反应较少且轻微。
Objective To compare the efficiency of ursodeoxycholic acid combined with domperidone or mosapride in the treatment of patients with primary bile reflux gastritis( PBRG).Methods Totally 86 patients with PBRG from May 2017 to August 2018 were selected and randomly divided into group A and group B,43 cases in each group. Group A was treated with ursodeoxycholic acid combined with domperidone,while group B was treated with ursodeoxycholic acid combined with mosapride. After one month of treatment,the clinical efficiency,scores of clinical symptoms and incidence of adverse reactions were compared between the two groups. Results The total effective rate in group A was 83. 72%,which was higher than 76. 74% in group B( P > 0. 05). One month after treatment,the scores of clinical symptoms such as abdominal pain,fullness,nausea and vomiting were obviously lower than those before treatment in both groups,and the scores of the above symptoms in group A were lower than those in group B( P > 0. 05). The incidence rate of adverse reactions in group A was 9. 30%,which was lower than 13. 95% in group B( P > 0. 05). Conclusion Ursodeoxycholic acid combined with domperidone or mosapride is safe and effective in the treatment of patients with PBRG,which can obviously improve the gastric discomfort symptoms,and the adverse reactions are less and mild.
Objective To compare the efficiency of ursodeoxycholic acid combined with domperidone or mosapride in the treatment of patients with primary bile reflux gastritis( PBRG).Methods Totally 86 patients with PBRG from May 2017 to August 2018 were selected and randomly divided into group A and group B,43 cases in each group. Group A was treated with ursodeoxycholic acid combined with domperidone,while group B was treated with ursodeoxycholic acid combined with mosapride. After one month of treatment,the clinical efficiency,scores of clinical symptoms and incidence of adverse reactions were compared between the two groups. Results The total effective rate in group A was 83. 72%,which was higher than 76. 74% in group B( P > 0. 05). One month after treatment,the scores of clinical symptoms such as abdominal pain,fullness,nausea and vomiting were obviously lower than those before treatment in both groups,and the scores of the above symptoms in group A were lower than those in group B( P > 0. 05). The incidence rate of adverse reactions in group A was 9. 30%,which was lower than 13. 95% in group B( P > 0. 05). Conclusion Ursodeoxycholic acid combined with domperidone or mosapride is safe and effective in the treatment of patients with PBRG,which can obviously improve the gastric discomfort symptoms,and the adverse reactions are less and mild.
引文
[1]宋红勇.联合熊去氧胆酸治疗原发性胆汁反流性胃炎的效果分析[J].中国实用医药,2016,11(25):162-163.
[2]杨志广.熊去氧胆酸联合枸橼酸莫沙必利治疗胆汁反流性胃炎疗效分析[J].内蒙古医学杂志,2016,48(4):432-434.
[3]刘敏.熊去氧胆酸联合铝碳酸镁、莫沙必利治疗胆汁反流性胃炎的临床观察[J].中国医药指南,2015,13(23):115-116.
[4]苗中兴,王玉杰,徐皓.熊去氧胆酸联合莫沙必利治疗胆汁反流性胃炎疗效分析[J].中国现代药物应用,2016,10(2):146-147.
[5]陈伟民.莫沙必利与多潘立酮治疗原发性胆汁反流性胃炎的效果分析[J].中国现代药物应用,2013,7(23):108-109.
[6]刘芳,姚萍.原发性胆汁反流性胃炎与胃食管反流病的关系[J].世界华人消化杂志,2012,20(8):685-689.
[7]李小艺,麦智艺,吴飞燕,等.熊去氧胆酸辅助治疗原发性胆汁反流性胃炎疗效评价[J].吉林医学,2014,35(4):787-788.
[8]Matsuhisa T,Arakawa T,Watanabe T,et al.Relation between bile acid reflux into the stomach and the risk of atrophic gastritis and intestinal metaplasia:a multicenter study of 2283cases[J].Dig Endosc,2013,25(5):219-225.
[9]Jurgens S,Meyer F,Spechler S J,et al.The role of bile acids in the neoplastic progression of Barrett's esophagus a short representative overview[J].Z Gastroenterol,2012,50(9):1028-1034.
[10]侯叶廷,胡海清,苏秉忠.原发性胆汁反流性胃炎的研究进展[J].中华胃肠内镜电子杂志,2015,2(1):3-5.
[11]郑忠法,舒正方,余文宇.胆汁反流性胃炎与幽门螺杆菌感染的相关性分析[J].中华医院感染学杂志,2013,23(23):5709-5710.
[12]梁龚山,杨阳.莫沙必利与多潘立酮对原发性胆汁反流性胃炎的治疗效果分析[J].中国医学前沿杂志:电子版,2014,6(10):144-146.
[13]Lionel,Rebibo T,Yzet C,et al.Frey procedure for the treatment of chronic pancreatitis associated with common bile duct stricture[J].Hepatobiliary Pancreat Dis Int,2013,12(6):637-644.
[14]黄德富.熊去氧胆酸联合莫沙必利治疗胆汁反流性胃炎疗效分析[J].实用药物与临床,2014,17(2):230-233.
[15]陈国毅.原发性胆汁反流性胃炎的治疗特点分析[J].中外医学研究,2011,9(36):163-164.
[16]王志宁,袁晓荚.原发性胆汁反流性胃炎治疗及其临床病理分析[J].重庆医学,2009,38(10):1227-1228,1230.
[2]杨志广.熊去氧胆酸联合枸橼酸莫沙必利治疗胆汁反流性胃炎疗效分析[J].内蒙古医学杂志,2016,48(4):432-434.
[3]刘敏.熊去氧胆酸联合铝碳酸镁、莫沙必利治疗胆汁反流性胃炎的临床观察[J].中国医药指南,2015,13(23):115-116.
[4]苗中兴,王玉杰,徐皓.熊去氧胆酸联合莫沙必利治疗胆汁反流性胃炎疗效分析[J].中国现代药物应用,2016,10(2):146-147.
[5]陈伟民.莫沙必利与多潘立酮治疗原发性胆汁反流性胃炎的效果分析[J].中国现代药物应用,2013,7(23):108-109.
[6]刘芳,姚萍.原发性胆汁反流性胃炎与胃食管反流病的关系[J].世界华人消化杂志,2012,20(8):685-689.
[7]李小艺,麦智艺,吴飞燕,等.熊去氧胆酸辅助治疗原发性胆汁反流性胃炎疗效评价[J].吉林医学,2014,35(4):787-788.
[8]Matsuhisa T,Arakawa T,Watanabe T,et al.Relation between bile acid reflux into the stomach and the risk of atrophic gastritis and intestinal metaplasia:a multicenter study of 2283cases[J].Dig Endosc,2013,25(5):219-225.
[9]Jurgens S,Meyer F,Spechler S J,et al.The role of bile acids in the neoplastic progression of Barrett's esophagus a short representative overview[J].Z Gastroenterol,2012,50(9):1028-1034.
[10]侯叶廷,胡海清,苏秉忠.原发性胆汁反流性胃炎的研究进展[J].中华胃肠内镜电子杂志,2015,2(1):3-5.
[11]郑忠法,舒正方,余文宇.胆汁反流性胃炎与幽门螺杆菌感染的相关性分析[J].中华医院感染学杂志,2013,23(23):5709-5710.
[12]梁龚山,杨阳.莫沙必利与多潘立酮对原发性胆汁反流性胃炎的治疗效果分析[J].中国医学前沿杂志:电子版,2014,6(10):144-146.
[13]Lionel,Rebibo T,Yzet C,et al.Frey procedure for the treatment of chronic pancreatitis associated with common bile duct stricture[J].Hepatobiliary Pancreat Dis Int,2013,12(6):637-644.
[14]黄德富.熊去氧胆酸联合莫沙必利治疗胆汁反流性胃炎疗效分析[J].实用药物与临床,2014,17(2):230-233.
[15]陈国毅.原发性胆汁反流性胃炎的治疗特点分析[J].中外医学研究,2011,9(36):163-164.
[16]王志宁,袁晓荚.原发性胆汁反流性胃炎治疗及其临床病理分析[J].重庆医学,2009,38(10):1227-1228,1230.